Eton Q2 product sales $18.9M (+108% YoY); non-GAAP EPS $0.03; raises revenue run-rate guidance

Eton Pharmaceuticals, Inc.

Q2 product sales $18.9M, up 108% YoY; GAAP EPS $(0.10), non-GAAP EPS $0.03.
Adjusted EBITDA $3.1M vs ($1.6M) prior year; adjusted gross margin improved to 75%.
Launched KHINDIVI (hydrocortisone oral solution) in June; INCRELEX reached 100 active patients ahead of year-end guidance.
Company projects $80M annual revenue run rate in Q3, one quarter ahead of prior outlook.
ET-600 NDA accepted with PDUFA date Feb 25, 2026; second patent granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.